High-density lipoprotein cholesterol and multiple sclerosis: a systematic review and meta-analysis
Archives of Medical Science – Atherosclerotic Diseases · 02.06.2025 · 10 (1) · 69-77
DOI: 10.5114/amsad/204578 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archives of Medical Science – Atherosclerotic Diseases, online erschienen am 02.06.2025. Verfasst von Anastasios Makris und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by demyelination and axonal degeneration. Evidence has shown that lipid metabolism is associated with MS clinical outcomes. The aim was to systematically investigate the association between high-density lipoprotein cholesterol (HDL-C) and disease activity in MS. Material and methods Medline via PubMed, the Cochrane Library and Clinicaltrials.gov databases were searched for studies with data on HDL-C in patients with MS. A qualitative synthesis of published prospective and retrospective studies on the role of HDL-C and other lipid profile parameters in MS was performed. Additionally, a meta-analysis on HDL-C mean differences (MD) between relapsing remitting MS (RRMS) cases and healthy controls (HC) was performed.
Results
Literature search identified 13 eligible studies evaluating the HDL-C levels of RRMS patients. In total, 1692 participants were included, 859 of which were RRMS patients, and 833 were HC. The pooled analysis demonstrated that RRMS patients had significantly lower HDL-C levels compared with HC (MD: –3.35 mg/dl, 95% CI (–5.69, –1.01), p = 0.005). Regarding triglycerides (TG) and total cholesterol (TC), the pooled analysis from 11 and 13 studies, respectively, showed significantly higher TG (MD = 26.33, 95% CI (15.03, 37.62), p < 0.00001) and TC levels (MD = 11.03, 95% CI (0.45, 21.60), p = 0.04) in RRMS versus HC. No significant differences were observed in low-density lipoprotein cholesterol levels between RRMS and HC.
Conclusions
HDL-C levels were significantly decreased in RRMS patients compared with HC. HDL-C and other lipid profile parameters should be considered in the assessment of patients with RRMS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- School of Medicine, European University Cyprus, Nicosia, Cyprus.
- Department of Internal Medicine, University Hospital of Ioannina, Faculty of Medicine, University of Ioannina, Ioannina, Greece.
- Department of Nursing, School of Health Sciences, University of Ioannina, Ioannina, Greece.
- Department of Internal Medicine, German Medical Institute, Limassol, Cyprus.
Zitieren
APA
Makris, A., Palli, N., Liontos, A., Rizos, E. C., Tsioutis, C., Papadopoulos, D., & Agouridis, A. P. (2025). High-density lipoprotein cholesterol and multiple sclerosis: a systematic review and meta-analysis. Archives of Medical Science – Atherosclerotic Diseases, 10(1), 69-77. https://doi.org/10.5114/amsad/204578
Vancouver
Makris A, Palli N, Liontos A, Rizos EC, Tsioutis C, Papadopoulos D, et al. High-density lipoprotein cholesterol and multiple sclerosis: a systematic review and meta-analysis. Archives of Medical Science – Atherosclerotic Diseases. 2025;10(1):69-77. doi:10.5114/amsad/204578
BibTeX
@article{Makris2025,
author = {Makris, Anastasios and Palli, Nikoletta and Liontos, Angelos and Rizos, Evangelos C and Tsioutis, Constantinos and Papadopoulos, Dimitrios and Agouridis, Aris P},
title = {High-density lipoprotein cholesterol and multiple sclerosis: a systematic review and meta-analysis},
journal = {Archives of Medical Science – Atherosclerotic Diseases},
year = {2025},
volume = {10},
number = {1},
pages = {69--77},
doi = {10.5114/amsad/204578}
}
EUVIMED